Patent · US Active

Method of inhibiting miR-33 using a modified oligonucleotide

US8809294B2 · kind B2 · utility

6Cited by

16References

25Claims

0Family size

Assignee

Regulus Therapeutics Inc. · US

Inventors

Christine Esau · Village of La Jolla, US
Bridget Lollo · Encinitas, US
C. Frank Bennett · Carlsbad, US
Susan M. Freier · San Diego, US
Richard H. Griffey · Vista, US
Brenda F. Baker · Carlsbad, US
Timothy Vickers · Vista, US
Eric G. Marcusson · San Francisco, US
Erich Koller · Lenzburg, CH
Eric E. Swayze · Carlsbad, US
Ravi Jain · Bound Brook, US
Balkrishen Bhat · Carlsbad, US
Eigen Peralta · San Diego, US

Key dates

Filing date	Jul 2, 2012
Grant date	Aug 19, 2014
Priority date	—
Expiry date	Jul 2, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/50
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.